Clinical Trial Update: Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating safety and changes in disease activity for oral venetoclax in combination with azacitidine (SC or IV) in newly diagnosed acute…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Azacitidine (Vidaza) (azacitidine)
• Venetoclax (Venclexta) (venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Acute Myeloid Leukemia | Phase 4 | Status: RECRUITING